INFORM			LOSU		ATION	ATT	Y. DOC	KET NO	. PC10761	Α	SERIAL NO	09/9	38,70	<u> </u>
INFORM (Use	sever	al she	JRADEN	ecessa	ry)	APP	LICANT	МО	RSEY, ET	AL.				-1
_									UST 24, 20	01	GROUP	.1640	5/64	4
						U.S. P	ATENT	DOCUM					FILING D	
EXAMINER INITIAL				DOCL	IMENT NUMB	ER	 		DATE	NAME	CLASS	SUBCLASS	IF APPROPE	IATE
	i										MAR 2	2002		
							Ì							
										TEC	H CENTER	1600/29	90	
	\dashv													
	-	\dashv												
					FO	RFIG	N PATE	NT DO	CUMENTS					
										COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
			DOC	UMENT NU	MBER				DATE	COUNTRY	CDAGG	00000100	YES	NO
									4/02	PCT				
Putt		9	3	0	5	8	1	0	4/93		_			
\rightarrow		9	8	2	4	8	0	8	6/98	PCT	-			
		9	9	6	7	2	9	3	12/99	PCT			-	
						, ,							<u> </u>	
													-	-
													-	-
														<u> </u>
														L
		**												
			OTHE	R DOC	<u> </u>	S (Incl	uding Au	ıthor, Ti	tle, Date, P	ertinent Pag	es, Etc.)		<u> </u>	
	1											a a Phasa l	Dienlav	
PUR		SHAK Librar	(IB, ET A y; Clinica	L.; Identif al and Exp	fication of Formation	Peptide Aliergy;	Vol. 30 No	ognized in the contract of the	by a Human (c es 1041-1046	gG Autoanti-IgE (2000) XP0010)55645.			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

ATTY, DOCKET NO. PC10761A

SERIAL NO

MORSEY, ET AL. APPLICANT

(Use s	everai si	neets II I	ecessa	<i>'</i> ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	 	2107 11 11			0.5	0110.4	5 12%	_	l
								JST 24, 2	2001 GRO	OUP 169	% ~	-	H
					U.S. P	ATENT	DOCUM	IENTS		T :: [CLASS	FILING D	L ATE
AMINER NITIAL			DOC	UMENT NUN	MBER			DATE	NAME	CLASS	LASS	APPROPR	
	4	9	8	0	2	8	6	12/90	Morgan, et al.				
	5	4	3	6	1	4	6	7/95	Shenk, et al.				
	5	6	0	1	8	2	_ 1	2/97	Stanworth, et al.				
	5	6	5	3	9	8	0	8/97	Hellman				
										<u> </u>			
				F	OREIG	N PATE	NT DOC	UMENT	\$ 		ı———		
		DO	SUMENT N	UMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATIC
			Δ									YES	N
	0	2	6	3	6	5	5	4/88	EP				\vdash
	9	2_	0_	6_	1_	88	0	4/92	PCT			-	\vdash
	9	2	2	0	3	11	6	11/92	PCT			-	Ł
	9	2	2	2	6	3	5_	12/92	PCT	-		-	╀
	9	3	1	4_	1	8	8	7/93	PCT	-	ļ · · ·	-	+
	9	3	2	0	2	×	1_	10/93	PCT	-		 	+
	9	4	0_	8_	5_	9	8	4/94	PCT			-	ł
	9_	4	1_1_	2	6_	4	10	6/94	PCT			+-	+
	9	7	3	1_	9	4	8	9/97	PCT			+-	+
			<u> </u>		<u> </u>		<u> </u>	1			<u> </u>	<u> </u>	
		отн	R DO	CUMEN	TS (Incl	luding Au	uthor, Ti	tle, Date,	Pertinent Pages,	Etc.)			_
1.	Bur	t, et al.; E	ur. J. Imn	nunol.; Int	ibition of	Binding of	Rat IgE to	o rat mast C	Cells by Synthetic IgE I	Peptides;	Vol. 17:437	-440 <u>(1</u>	98
2.	Hel	lm, et al.; l	Nature; T	ne Mast C	ell Bindin	g Site on I	Human Im	munoglobu	lin E; Vol. 331: 180-18	3 (1988).			
3.	He ant	Helm, et al.; Proc. Natl. Acad. Sci.; Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ε-chain fragment of 76 amino acids; Vol. 86, p. 9469 (1989).											
4.		Vercelli, et al.; Nature; The B-Cell binding site on human immunoglobulin E; Vol. 338:649-65 (1989).											
5.	Nic pe	o, et al.; FE ptide fragn	BS Lette nents; 31	er; Inhibitio 9:225-228	on of pass 3 (1993).	sive sensit	ization of	human peri	pheral basophils by sy	nthetic hu	man immun	oglobu	lin
6.	Nic	o, et al.; Fi ol. 314, No	BS Lette 3, p 229	er; Inhibitio -231 (199	on of pass 2).	sive cutane	eous anap	hylaxis by	synthetic human immu	inoglobulir	E peptide	fragme	nt
7.			The 1 of	Dielogiaa	I Chamiei	try; Purifica eptor; Vol.	ation and 0 268, No.	10, p. 1011	ation of Human Recon 8-13127 (1993).	nbinant Igl	E-Fc Fragm	ents th	at
	1		1 -					$\neg /$	18/02			•	

INFORMATION DISCLOSURE CITATION LIST.DOT, 3/99

Express Mail No. EL768261578US

1	OIPE	
B	JAN 2 4 2002	
V	A	

		B JAN 2 4 2002 W		<u> </u>
INFOR	MATIC	N DISCLOSURE CITATION	ATTY. DOCKET NO. PC10761A	SERIAL NO. 209/938, 100
		eral sheets if necessary)	APPLICANT MORSEY, ET AL.	- B : リ
()	.00 001		FILING DATE AUGUST 24, 2001	GROUP 16418 8 S
8.		Vangelista, et al.; The J. of Clinical I for human IgE-FcaRI interaction; Vo	nvestigation; The Immunoglobulin-like modules Cε3 and I. 103: p. 1571-1578 (1999).	g2 are the minima its neces any
9.			ology: IgE Structure-Function relationships Defined by Se	equence Directed Antibodies
10.		19:1015-1023 (1989).	of Immunology; Mapping of Murine IgE Epitopes Involved	
11.		Weetall, et al.; The J. of Immunolog Chimeric lg ¹ : 145:3849-3854 (1990	y; Mapping the Site of Interaction between Murine IgE ar).	nd its High Affinity Receptor with
12.		Presta, et al.; The J. of Biological C 269:26368-26373 (1994).	hemistry; The Binding Site on Human Immunoglobulin E	for Its High Affinity Receptor;
13.		Nissim, et al.; The J. of Immunolog 150:1365-1374 (1993).	y; Fine Specificity of the IgE Interacton with the Low and	High Affinity Fc Receptor ¹ ;
14.		Properties with the High-Affinity Re	ology; Monoclonal Antibodies Against Human IgE, Identi coptor Binding Site; 28:839-844 (1991).	
15.		Keegan, et al.; Molecular Immunol Chimeric IgE to Further Define the	ogy; Characterization of New Rat Anti-Mouse IgE Monoc Site that interacts with Fc _e RII and Rc _e RI; 28:1149-1154 (lonals and their use along with 1991).
16.		Hook, et al.; Molecular Immunolog	y; Monoclonal Antibodies Defining Epitopes on Human Iç	E; 28:631-639 (1991).
17.		Takemoto, et al.; Microbiol. Immur Sites of High and Low Affinity IgE	ology: Anti-Human IoE Monoclonal Antibodies Recogniz	ing Epitopes Related to the Binding
18.			nology; Anti-IgE Monoclonal Antibodies Directed at the Fo	Receptor Binding Site; 25:705-711
19.		Chang, T.W.: Nature: The Pharma	cological Basis of Anti-IgE Therapy, 157-162 (2000).	
			gy; Humanization of an Antibody Directed Against IgE; 15	51:2623-2632 (1993).
20.			munol.; Biological Activities of Anti-IgE Antibodies; 102:	
21.		Stadler, et al., Int. Arch Allergy Int	pitope-Specific Antibody Response to IgE by Mimotope	Immunization ¹ ; 160:3515-3321.
22.		Rudolf, et al.; J. of immunology, E	mmunology; A Murine Model of IgE-mediated cow's milk	hypersensitivity; 103:206-214 (1999).
23.	+-			
24.		107:693-702 (2001).	mmunology; Murine Model of Atopic Dermatitis Associate	
25.			Science; The Atopic Dog: A Model for Food Allergy; Vol. 4	
26.		1) 37:361-375 (2000).	nunology; Identification, cloning, and characterization of a	
27.		Underwood, et al.; Immunology; Norway rat: the Effects of Ricin;	gE Production, Antigen-induced airway inflammation and 85:256-261 (1995).	d Airway Hyperreactivity in the Brown
28.		Underwood, et al.; Int. Arch Aller Hyperresponsiveness in the Rat	gy Immunology; Ricin Icreases IgE Levels and Airway In 107:119-121 (1995).	flammation but Not
h	$\overline{}$			

Diaz-Sanchez, et al.; Immunology; Generation of a long-lived IgE Response in High and Low Responder Strains of rat by conditions and Antigen; Immunology; 72:297-303 (1991).

29.



INFORMATION DISCLOSURE CITATES (Use several sheets if necessary)

ATTY. DOCKET NO. PC10761A

SERIAL NO.

MORSEY, ET AL. APPLICANT

/	I lea	CAVE	eral sheets if necessary)	AFFEIGAIVI MOTIO	
(USC	3040		FILING DATE AUGUST 24, 2001	GROUP 1644 3
30.			Noble, et al.; Immunology; Eliminatio cytokines IL-4, IL-5 and IL-10; 80:32	n of IgE Regulatory Rat CD8 [*] T Cells in Vivo Incre 6-329 (1993).	ases the Co-ordinate Expression of Th2
31.			Diaz-Sanchez, et al.; Immunology; R Regulatory CD8* T Cells; 78:226-23	Ricin Enhances IgE responses by Inhibiting a Subp 6 (1993).	opulation of Early-Activated IgE
32.				Methods for Assessing the Statistical Significance	of Molecular Sequence Features by Usin
33.			Karlin, et al.; Proc. Natl. Acad. Sci.; 90, p. 5873-5877 (1993).	Applications and Statistics for Multiple High-scoring	g Segments in Molecular Sequences; Vol
—— 34.	<u> </u>			ci.; Improved Tools for Biological Sequence Compa	arison; Vol. 85, p. 24444-2448 (1988).
35.				ence Requirements of the SV40 Early Promoter R	
36.			Yamamoto, et al.; Cell; Identification 787-797 (1980).	n of a Functional Promoter in the Long Terminal Re	epeat of Rous Sarcoma Virus; Vol. 22, p.
37.			Wagner, et al.; Proc. Natl. Acad. Sc 78, No. 3, p. 1441-1445 (1981).	ci.; Nucleotide Sequence of the Thymidine Kinase (Gene of Herpes Simplex Virus Type 1; Vo
38.				of Metallothionein-thymidine Kinase Fusion plasmic	ds injected into Mouse Eggs; 296:39-42
39.			Villa-Komaroff, et al.; Proc. Natl. Ad	cad. Sci.; A Bacterial Clone Synthesizing Proinsulin	n; 75:3727-3731 (1978).
40.			DeBoer, et al.; Proc. Natl. Acad. So 21-25 (1983).	ci.; The tac promoter: A functional hybrid derived for	rom the trp and lac promoters; Vol. 80, p.
41.	1		Gilbert, et al.; Scientific American;	Useful Proteins from Recombinant Bacteria; 242:7	4-94 (1980).
42.			Torelli, et al.; Comput Appl. Biosci. homologous informational sequence	· Advance and Adam: Two algorithms for the anal	ysis of global similarity between
43.			Herrera-Estrella, et al.; Nucl. Acids vector; 303:209-213.	s Res.; Expression of chimaeric genes transferred	into plant cells using a Ti-plasmid-derived
44.	-			Abstract; Vol. 9, No. 12, p. 2871-2888 (1981).	<u>\</u> .
45.			Herrera-Estrella, et al.; Nature; 31		
46.			Swift, et al.; Cell; Tissue-Specific	Expression of the Rat Panreatic Elastase I Gene in	1 Transgenic Mice; 38:639-646 (1984).
47.			SV40 T Antigen Genes to Pancre	Symp. Quant. Biol.; Elastase I Promoter Directs Exactic Acinar Cells in Transgenic Mice; 50:399-409 (
48.			MacDonald, R.J.; Hepatology; Ex	pression of the Pancreatic Elastase I Gene in Tran	sgenic Mice; 7:425-515 (1987).
49.			virus 40 oncogenes; 315:115-122		
50.	.		Grosschedl, et al.; Cell; Introducti Cells and Synthesis of Functiona	ion of a μ Immunoglobulin Gene into the Mouse Ge I Antibody; 38:647-658 (1984).	erm Line: Specific Expression in Lymphoid
51				c oncogene driven by immunoglobulin enhancers in	nduces lymphoid malignancy in transgenic
			(SI	7/18/02	

/	6	IE	E	
PA	JAN	2	4 2002	17 30,

(Use several sheets if necessary)

ATTY. DOCKET NO. PC10761A

SERIAL NO.

MORSEY, ET AL. APPLICANT

FILING DATE AUGUST 24, 2001

GROUP

	FILING DATE AUGUST 24, 2001 GROUP (647) NO I
52.	Alexander, et al.; Molecular and Cellular Biology; Expression of the c-myc Oncogene under control of an immuno enhancer in Eµ-myc Transgenic Mice; Vol. 7, No. 4, p. 1436-1444 (1987).
53.	Pattengale, et al.; Cell; Consequences of Widespread Deregulation of the c-myc Gene in Transgenic Mice: Multiple Neoplasms and Normal Development; Vol. 45, p. 485-495 (1986).
54.	Leder, et al.; Cell; Consequences of Widespread Deregulation of the c-myc gene in transgenic mice: Multiple Neoplasms and Normal Development; 45:485-495 (1986).
55.	Pinkert, et al.; Genes and Development; An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice; 1:268-276 (1987).
56.	Krumlauf, et al.; Molecular and Cellular Biology; Developmental Regulation of α-Fetoprotein Genes in Transgenic Mice; Vol. 5, No. 7, p. 1639-1648 (1985).
57.	Hammer, et al.; Science; Diversity of Alpha-Fetoprotein Gene Expression in Mice Is Generated by a Combination of Separate Enhancer Elements, 235:53-58 (1987).
58.	Kelsey, et al.; Genes & Development; Species- and tissue-specific expression of human α₁-antitrypsin in transgenic mice; 1:161-171 (1987).
	Magram, et al.; Nature; Developmental regulation of a cloned adult β-globin gene in transgenic mice; 315:338-340 (1985).
59. 60.	Kollias, et al.; Cell; Regulated Expression of Human ^A Y-, β-, and Hybrid Υβ-Globin Genes in Transgenic Mice: Manupulation of the Developmental Expression Patterns; Vol. 46, 89-94 (1986).
61.	Readhead, et al.; Cell; Expression of a Myelin Basic Protein Gene in Transgenic Shiverer Mice: Correction of the Dysmyelinatin Phenotype; Vol. 48, 703-712 (1987).
62.	Shani, M.; Nature; Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice; Vol. 314:283-286 (1985).
63.	Reecy, et al.; Animal Biotechnology; Multiple Regions of the Porcine α-Skeletal Actin Gene Modulate Muscle-specific Expression in Cell Culture and Directly Injected Skeletal Muscle; 9(2), p. 101-120 (1998).
64.	Mason, et al.; Science; The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy; Vol. 234:1273-1378
65.	(1986). Wigler, et al.; Cell; Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells; Vol. 11 p. 223-232
66.	(1977). Szybalska, et al.; Proc. Natl., Acad Sci.; Genetic of Human Cell Lines, IV.; 48:2026-2034 (1962).
67.	Lowy, et al.; Cell; Isolation of Transforming DNA: Cloning the Hamster aprt Gene; Vol. 22, p. 817-823 (1980).
68.	Wigler, et al.; Proc. Nalt. Acad. Sci.; Transformation of mammalian cells with an amplifiable dominant-acting gene; Vol. 77, No. 6, p. 3567-3570 (1980).
69.	O'Hare, et al.; Proc. Natl. Acad. Sci.; Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmic expressing a prokaryotic dihydrofolate reductase; 78:1527 (1981).
70.	Mulligan, et al.; Proc. Natl. Acad. Sci.; Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase; Vol. 78, No. 4, p. 2072-2076 (1981).
71.	Colbere-Garapin, et al.; J. Mol. Biol.; A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells; 150:1-14 (1981).
72.	Santerre, et al.; Gene; Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers mouse L cells; 30:147-156 (1984).
73.	Goldspiel, et al.; Clinical Pharmacy; Clinical Frontiers; Vol. 12, p. 488-505 (1993).
	- 1/1//0>

/	OIF) E 16	
(2	NAL	1 4 2002	FIGE
			C7

(Use several sheets if necessary)

ATTY. DOCKET NO. PC10761A

SERIAL NO.

MORSEY, ET AL. APPLICANT FILING DATE AUGUST 24, 2001

GROUP

			29
\x4.			Wu, et al.; Biotherapy; Delivery systems for gene therapy; 3:87-95 (1991).
75.			Tolstoshev; Ann. Rev. Pharmacol. Toxicol.; Gene Therapy, Concepts, Current Trials and Future Directions; 32:573-596 (1993).
76.			Mulligan, R.; Science; The Basic Science of Gene Therapy; 260:926-932 (1993).
77.		/	Morgan and Anderson, et al.; Ann. Rev. Biochem.; Human Gene Therapy; 62:191-217 (1993).
78.			Robinson, C.; Tibtech; Gene Therapy – proceeding from laboratory to clinic; 11(5):155-215 (1993).
79.			Koller, et al.; Proc. Natl. Acad. Sci.; Inactivating the β₂-microglobulin locus in mouse embryonic stem cells by homologous recombination; Vol. 86, p. 8932-8935 (1989).
80.			Koller, et al.; Proc. Natl. Acad. Sci.; Inactivating the β₂-microglobulin locus in mouse embryonic stem cells by homologous recombination; Vol. 86, p. 8932-8935 (1989).
81.			Zijlstra, et al.; Nature; Germ-line transmission of a disrupted β ₂ -microglobulin gene produced by homologous recombination in embryonic stem cells; 342:435-438 (1989).
82.		····	Wu, et al.; J. Biol. Chem.; Recetor-mediated in Vetro Gene Transformation by a Soluble DNA Carrier System; Vol. 262, No. 10, p. 4429-4432 (1987).
-			Miller, et al.; Meth. Enzymol.; Use of Retroviral Vectors for Gene Transfer and Expression; 217:581-599.
83. 84.			Clowes, et al.; J. Clin. Invest; Long-Term Biological Response of Injured Rat Carotid Artery Seeded with Smooth Muscle Cells Expressing Retrovirally Introduced Human Genes; 93:644-651 (1994).
85.			Kiem, et al.; Blood; Retrovirus-Mediated Gene Transduction Into Canine Peripheral Blood Repopulating Cells; 83:1467-1473 (1994).
	+-	┢╴	Salmons, et al.; Human Gene Therapy; Targeting of Retroviral Vectors for Gene Therapy; 4:129-141 (1993).
86.	-	-	Grossman, et al.; Current Opinion in Genetics and Devel.; Retroviruses: delivery vehicle to the liver; 3:110-114 (1993).
87.	-		Bout, et al.; Human Gene Therapy; Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium; 5:3-10 (1994).
89.	-		Rosenfeld, et al.; Science; Adenovirus-Mediated Transfer of a Recombinant q-1-Antitrypsin Gene to the Lung Epithelium in
90.	+		Vivo; 252:431-434 (1991). Rosenfeld, et al.; Cell; In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium; 68:143-155 (1992).
91.	-	-	Mastrangeli, et al.; J. Clin. Invest.; Diversity of Airway Epithelial Cell Targets for the Vivo Resombinant Adenovirus-mediated Gene Transfer; 91:225-234 (1993).
92.			Wang, et al.; Gene Therapy; A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal generegio deletions; 2:775-783 (1995).
	+	+	Walsh, et al.; Proc. Soc. Exp. Biol. Med.; Gene Therapy for Human Hemoglobinopathies; 204:289-300.
93.		+	Loeffler, et al; Methods in Enzymology; 217:599-618 (1993).
94.		\top	Cotten, et al.; Methods in Enzymology; Receptor-Mediated Transport of DNA into Eukaryotic Cells; Vol. 217, p. 618-644 (1993).
95.		+-	Cline, M.; Pharmac. Ther.; Perspectives for Gene Therapy; 29:69-92.
96		+	Stemple, et al.; Cell; Isolation of a Stem Cell for Neurons and Glia from the Mammalian Neural Crest; 71:973-985 (1992)
n 9/	. 1	- 1	_ / _//

		a			
INFOF	RMATIC	ON DISCLOSURE CITATION	ATO. DOCKET NO. PC10761A	SERIAL NO.	09/538,700
		reral sheets if necessary)	APPLICANT MORSEY, ET AL.		7 0
, ,)3C 3CV	oral anodio ii iio coccasi,	FILING DATE AUGUST 24, 2001	GROUP 16	44 86 PO
00		Rheinwald J. Methods in Cell Biolog	gy; Serial Cultivation of Normal Human Epide	ermal Keratinocytes; 21a:229	-2554
98.		Dittellions et al.: Mayo Clinic Proc.: N	New Techniques for the In Vitro Culture of Hul h Extensive Burns; 61:771-777 (1986).		
100.			of Drug Delivery; 249:1527-1533 (1990).		
101.			y of Infectious Diseases and Cancer; Liposon	me Encapsulated Doxorubici	n Preliminary
102.		Sefton, M.; CRC Crit Ref. Biomed. E	ng.; Implantable Pumps; 14:201-240 (1987).		
103.		D total of all Surgary Lang-Ter	m, continuous intravenous heparin administra enous thrombosis; 88:507-116 (1980).		on pump in
104.			preliminary trial of the programmable implant	table medication system for i	nsulin delivery;
105.		Levy, et al.; Science; Inhibition of C 228:190-192 (1985).	alcification of Bioprosthetic Heart Valves by L	ocal Controlled-Release Dip	hosphonate;
106.		During, et al.; Am. Neurological Ass 25:351-356 (1989).	soc.; Controlled Release of Dopamine from a	polymeric brain implant: In v	ivo characterizati
107.		Howard, et al.; J. Neurosurg; Intrac	erebral drug delivery in rats with lesion-induc-	ed memory deficits; 71:105-1	112 (1989).
108.			olled Release supra Vol. II p. 115-138 (1984)		
109.			Antennapedia homeobox peptide regulates r		64-1868 (1991).
110.			ol, Chem. Phys.; Chemical and Physical Stru	_	
EXAMI	NER	Ply N. He	DATE CONSIDERED	7/18/02	
EXAMINE with next	R: Initial if communicat	reference considered, whether or not citation is in coion to applicant.	onformance with MPEP 609; Draw line through citation if not	in conformance and not considered. Ir	aclude copy of this form

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE